Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 06:20PM GMT
Release Date Price: $82.22 (+8.48%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Good afternoon. Welcome back to the Bank of America Healthcare Conference. It's my pleasure to have our next presenting company with us, Neurocrine. We've had the pleasure of covering Neurocrine now for several years. So sitting next to me are Kevin and Matt. I will let each of you introduce yourselves. And then maybe, Kevin, you can give us an overview of what's been happening with the company over the last year or so, and then we can go into a little bit more detailed Q&A, if that works.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

That's great. Thank you, Tazeen. It's a pleasure being here in person with you and having the opportunity to be able to speak at this conference. So I'm Kevin Gorman. I'm the CEO of Neurocrine.

Matthew C. Abernethy;Kevin C. Gorman
Neurocrine Biosciences, Inc. - CFO;

Matt Abernethy, CFO, joined the company about 4.5, 5 years ago.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot